Advances in adenoviral vectors: from genetic engineering to their biology

被引:136
作者
Yeh, P
Perricaudet, M
机构
[1] CNRS URA 1301/Rhone-Poulenc Rorer G., Lab. de Genet. des Virus Oncogenes, Institut Gustave Roussy
[2] CNRS URA 1301/Rhone-Poulenc Rorer G., Lab. de Genet. des Virus Oncogenes, Institut Gustave Roussy, 94805 Villejuif Cedex
关键词
adenovirus; viral capsid; DNA replication; gutless;
D O I
10.1096/fasebj.11.8.9240963
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ad2 and Ad5 belong to a group of human cytolytic viruses that target the respiratory airways for reproduction, whereas latent infections establish within other tissues. Signals therefore exist that control this dichotomic process in different cell types, perhaps including cis and/or trans elements of viral origin. Since 1993, Ad2- and Ad5-based adenoviruses lacking all or part of the El regulatory region have been undergoing evaluation in phase I trials that target cancer and cystic fibrosis. These viruses are extremely attenuated and actually do not reproduce in most human cells. However, they retain most of the virus genetic program and often promote a significant cytotoxicity after infection, emphasizing the need to further cripple the virus biology to extend the duration of transgene expression, if required. We will review the strategies currently followed to engineer a professional lytic virus for epithelial cells into an innocuous gene delivery vehicle. Potential effects on the transducing properties of the vector that may result from the inactivation of viral activities that normally allow/regulate extrachromosomal gene expression during wild-type infection are discussed.
引用
收藏
页码:615 / 623
页数:9
相关论文
共 50 条
[41]   Peptide targeting of adenoviral vectors to augment tumor gene transfer [J].
Ballard, E. N. ;
Trinh, V. T. ;
Hogg, R. T. ;
Gerard, R. D. .
CANCER GENE THERAPY, 2012, 19 (07) :476-488
[42]   Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators [J].
Mowa, Mohube Betty ;
Crowther, Carol ;
Arbuthnot, Patrick .
EXPERT OPINION ON DRUG DELIVERY, 2010, 7 (12) :1373-1385
[43]   Use of chimeric adenoviral vectors to assess capsid neutralization determinants [J].
Roy, S ;
Clawson, DS ;
Calcedo, R ;
Lebherz, C ;
Sanmiguel, J ;
Wu, D ;
Wilson, JM .
VIROLOGY, 2005, 333 (02) :207-214
[44]   Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors [J].
Kreppel, Florian ;
Hagedorn, Claudia .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (05) :1-11
[45]   In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors [J].
Nicklin, SA ;
White, SJ ;
Nicol, CG ;
Von Seggern, DJ ;
Baker, AH .
JOURNAL OF GENE MEDICINE, 2004, 6 (03) :300-308
[46]   Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy [J].
Hauser, MA ;
Amalfitano, A ;
KumarSingh, R ;
Hauschka, SD ;
Chamberlain, JS .
NEUROMUSCULAR DISORDERS, 1997, 7 (05) :277-283
[47]   Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models [J].
Brunetti-Pierri, Nicola ;
Ng, Philip .
VIRUS GENES, 2017, 53 (05) :684-691
[48]   Increased protein expression from adenoviral shuttle plasmids and vectors by insertion of a small chimeric intron sequence [J].
Hermening, S ;
Kügler, S ;
Bähr, M ;
Isenmann, S .
JOURNAL OF VIROLOGICAL METHODS, 2004, 122 (01) :73-77
[49]   Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models [J].
Nicola Brunetti-Pierri ;
Philip Ng .
Virus Genes, 2017, 53 :684-691
[50]   Retargeting of adenoviral vectors to neurons using the HC fragment of tetanus toxin [J].
H Schneider ;
M Groves ;
C Mühle ;
P N Reynolds ;
A Knight ;
M Themis ;
J Carvajal ;
F Scaravilli ;
D T Curiel ;
N F Fairweather ;
C Coutelle .
Gene Therapy, 2000, 7 :1584-1592